Envelope gene evolution and HIV-1 neuropathogenesis
- PMID: 27135036
- PMCID: PMC4849130
- DOI: 10.4172/2314-7326.S2-003
Envelope gene evolution and HIV-1 neuropathogenesis
Abstract
In the era of combined antiretroviral therapy (cART), HIV-associated neurocognitive disorders (HAND) account for 40 to 56% of all HIV+ cases. During the acute stage of HIV-1 infection (<6 months), the virus invades and replicates within the central nervous system (CNS). Compared to peripheral tissues, the local CNS cell population expresses distinct levels of chemokine receptors, which levels exert selective pressure on the invading virus. HIV-1 envelope (env) sequences recovered from the brains and cerebrospinal fluid (CSF) of neurocognitively impaired HIV+ subjects often display higher nucleotide variability as compared to non-impaired HIV+ subjects. Specifically, env evolution provides HIV-1 with the strategies to evade host immune response, to reduce chemokine receptor dependence, to increase co-receptor binding efficiency, and to potentiate neurotoxicity. The evolution of env within the CNS leads to changes that may result in the emergence of novel isolates with neurotoxic and neurovirulent features. However, whether specific factors of HIV-1 evolution lead to the emergence of neurovirulent and neurotropic isolates remains ill-defined. HIV-1 env evolution is an ongoing phenomenon that occurs independently of neurological and neurocognitive disease severity; thus HIV env evolution may play a pivotal and reciprocal role in the etiology of HAND. Despite the use of cART, the reactivation of latent viral reservoirs represents a clinical challenge because of the replenishment of the viral pool that may subsequently lead to persistent infection. Therefore, gaining a more complete understanding of how HIV-1 env evolves over the course of the disease should be considered for the development of future therapies aimed at controlling CNS burden, diminishing persistent viremia, and eradicating viral reservoirs. Here we review the current literature on the role of HIV-1 env evolution in the setting of HAND disease progression and on the impact of cART on the dynamics of viral evolution.
Keywords: HIV; HIV-associated neurocognitive disorders; envelope; viral evolution.
Similar articles
-
Molecular Signatures of HIV-1 Envelope Associated with HIV-Associated Neurocognitive Disorders.Curr HIV/AIDS Rep. 2018 Feb;15(1):72-83. doi: 10.1007/s11904-018-0374-3. Curr HIV/AIDS Rep. 2018. PMID: 29460224 Review.
-
Longitudinal Analysis of Cerebrospinal Fluid and Plasma HIV-1 Envelope Sequences Isolated From a Single Donor with HIV Asymptomatic Neurocognitive Impairment.J Virol Antivir Res. 2015;4(1):10.4172/2324-8955.1000135. doi: 10.4172/2324-8955.1000135. J Virol Antivir Res. 2015. PMID: 26167513 Free PMC article.
-
Tracking the Emergence of Host-Specific Simian Immunodeficiency Virus env and nef Populations Reveals nef Early Adaptation and Convergent Evolution in Brain of Naturally Progressing Rhesus Macaques.J Virol. 2015 Aug;89(16):8484-96. doi: 10.1128/JVI.01010-15. Epub 2015 Jun 3. J Virol. 2015. PMID: 26041280 Free PMC article.
-
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.J Virol. 2005 Feb;79(3):1772-88. doi: 10.1128/JVI.79.3.1772-1788.2005. J Virol. 2005. PMID: 15650202 Free PMC article.
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
Cited by
-
Evidence of Divergent Amino Acid Usage in Comparative Analyses of R5- and X4-Associated HIV-1 Vpr Sequences.Int J Genomics. 2017;2017:4081585. doi: 10.1155/2017/4081585. Epub 2017 May 17. Int J Genomics. 2017. PMID: 28620613 Free PMC article.
-
Compartmentalization of Subtype A17 of Small Ruminant Lentiviruses between Blood and Colostrum in Infected Goats Is Not Exclusively Associated to the env Gene.Viruses. 2019 Mar 18;11(3):270. doi: 10.3390/v11030270. Viruses. 2019. PMID: 30889906 Free PMC article.
-
Molecular Signatures of HIV-1 Envelope Associated with HIV-Associated Neurocognitive Disorders.Curr HIV/AIDS Rep. 2018 Feb;15(1):72-83. doi: 10.1007/s11904-018-0374-3. Curr HIV/AIDS Rep. 2018. PMID: 29460224 Review.
References
-
- Heaton RKFD, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S, Corkran SH, Duarte NA, Clifford DB, Woods SP, Collier AC, Marra CM, Morgello S, Rivera Mindt M, Taylor MJ, Marcotte TD, Hampton Atkinson J, Wolfson T, Gelman BB, McArthur JC, Simpson DM, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I the CHARTER and HNRC Groups. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of Neurovirology. 2011;17:3–16. - PMC - PubMed
-
- Heaton RK, Clifford DB, Franklin DR, Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I Group C. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–2096. - PMC - PubMed
-
- Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, Moore D, Ellis R, Cherner M, Gelman B, Morgello S, Singer E, Grant I, Masliah E National Neuro ATC. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol. 2009;15:360–370. - PMC - PubMed
-
- Antinori A, A G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE. Updated Research Nosology for HIV Associated Neurocgonitive Disorders Neurology. 2007;69:1780–1799. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources